SPARC and central nervous system cancer: More importantly, to determine whether ZnPcS can be selectively targeted via SPARC overexpression in the glioma membrane, the selective inflow of ZnPcS was observed using U87-glioma cells that knocked out SPARC protein with CRISPR-Cas9.